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ABSTRACT: The use of biological systems to synthesize complex
therapeutic products has been a remarkable success. However,
during product development, great attention must be devoted to
deﬁning acceptable levels of impurities that derive from that
biological system, heading this list are host cell proteins (HCPs).
Recent advances in proteomic analytics have shown how diverse
this class of impurities is; as such knowledge and capability grows
inevitable questions have arisen about how thorough current
approaches to measuring HCPs are. The fundamental issue is how
to adequately measure (and in turn monitor and control) such a
large number of protein species (potentially thousands of
components) to ensure safe and efﬁcacious products. A rather
elegant solution is to use an immunoassay (enzyme-linked
immunosorbent assay [ELISA]) based on polyclonal antibodies
raised to the host cell (biological system) used to synthesize a
particular therapeutic product. However, the measurement is
entirely dependent on the antibody serum used, which dictates the
sensitivity of the assay and the degree of coverage of the HCP
spectrum. It provides one summed analog value for HCP amount; a
positive if all HCP components can be considered equal, a negative
in the more likely event one associates greater risk with certain
components of the HCP proteome. In a thorough risk-based
approach, one would wish to be able to account for this. These
issues have led to the investigation of orthogonal analytical
methods; most prominently mass spectrometry. These techniques
can potentially both identify and quantify HCPs. The ability to
measure and monitor thousands of proteins proportionally
increases the amount of data acquired. Signiﬁcant beneﬁts exist
if the information can be used to determine critical HCPs and
thereby create an improved basis for risk management. We
describe a nascent approach to risk assessment of HCPs based
upon such data, drawing attention to timeliness in relation to
biosimilar initiatives. The development of such an approach
requires databases based on cumulative knowledge of multiple risk
factors that would require national and international regulators,
standards authorities (e.g., NIST and NIBSC), industry and
academia to all be involved in shaping what is the best approach to
the adoption of the latest bioanalytical technology to this area,
which is vital to delivering safe efﬁcacious biological medicines of
all types.
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Introduction
During manufacturing of therapeutic proteins destined for use in
the clinic using cell-based systems, the product itself must be
puriﬁed from any cell-based impurities to an acceptable level before
administration in the clinic. Here, we focus upon impurities that
may be derived from mammalian expression systems (e.g., Chinese
hamster ovary [CHO] cells), whereby not only is the product of
interest secreted into the cell culture ﬂuid that is collected for
harvest, but host cell proteins (HCPs), nucleic acids, lipids, and
other cellular material that may be released into the culture media
along with product impurities (Guiochon and Beaver, 2011). HCPs
(e.g., see (Shukla et al., 2008)) and DNA (e.g., see (Zhang et al.,
2014a)), in particular, must be monitored and in the ﬁnal product,
the general guidelines are that there should be total amounts of less
than 100 ng/mL and 10 ng/dose of these impurities respectively
(Chon and Zarbis-Papastoitsis, 2011). However, this amount might
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be unacceptable for a particular HCP in terms of risk or product
degradation, for example, residual proteases (Gao et al., 2011;
Robert et al., 2009) that could potentially reduce the amount of
active drug present or in the worst-case scenario lead to the
development of immunogenic forms of the product.
The philosophy at the core of downstream processing for
biologics is the use of orthogonal puriﬁcation steps, that is,
separations based on a series of differing properties such as charge
followed by hydrophobicity. This arises because of the need to
separate product from the diverse spectrum of nucleic acid, lipid,
and protein (the host cell proteins, HCPs) impurities derived from
the host. Evaluating all the HCP components individually
traditionally created an unsustainable position; hence, currently,
we seek summative measures based on enzyme-linked immuno-
sorbent assays (ELISAs) using antibodies raised against the
spectrum of HCPs found in the host cell being used. Questions have
long been raised over issues associated with this approach which
will be the subject of further attention in this review; at this point,
these issues can be summarized as concerns as to whether all HCPs
are being measured (i) at all and (ii) with sufﬁcient sensitivity. This
is an evenmore difﬁcult question than it may ﬁrst appear to be as all
HCPs are not considered to be of equal importance (due to the risk
associated with each, a concept developed in this review); therefore,
the desired measurement sensitivity required for an individual HCP
varies accordingly.
Our ability to directly address this measurement challenge has
grown rapidly in the last decade. The demands of proteomics have
driven a proliferation in bioanalytical approaches with ever
increasing sensitivity, but which technologies can bring the greatest
added value to this sector? The challenge is to understand where
this analytical technology may best be deployed to improve the
safety and efﬁcacy of biologics during their development and
manufacture. This includes consideration of high-resolution
methods suited to the research laboratory environment which
may aid the creation of product and process understanding to those
to be consistently used for process monitoring during manufactur-
ing and for product release criteria. This has not gone unnoticed by
the community as testiﬁed by the literature reviewed here and
considerable conference activity, a good recent example of which is
BEBPA’s ﬁrst Annual European HCP Workshop May 15–16, 2014,
Dubrovnik, Croatia.
The presence of HCPs in biotherapeutic recombinant proteins
destined for the clinic presents a risk to the patient if not mitigated
against (Huang et al., 2009, Wang et al., 2009; Zhu-Shimoni et al.,
2014). One of the major risks that HCPs present is that of potential
immunogenicity, although current approaches to monitor and
measure HCP content in biologics manufactured from cell
expression systems do not provide the ability to judge the risk of
the presence of a particular HCP or group of HCPs. Very recently,
work has emerged that has begun to address this important issue
whereby in silico analysis can be undertaken in order to score the
relative risk of speciﬁc HCPs (Bailey-Kellogg et al., 2014) and others
have also raised the potential for risk assessment of HCPs
(Aboulaich et al., 2014; Zhu-Shimoni et al., 2014). However,
estimating relative risk alone may not be sufﬁcient. In order to
utilize such information to reduce the HCP risk, one must be able to
not only identify those HCPs that are present during bioprocessing
and in the ﬁnal product but also the amounts of these that are
present.
Further complicating any element of HCP risk is the nature of the
product itself. A number of reports have now shown that many of
the HCPs that are found in the elutes of chromatography steps,
particularly protein A afﬁnity chromatography for the puriﬁcation
of antibodies, are co-puriﬁed with the product due to interaction
with the product itself (Levy et al., 2014; Sisodiya et al., 2012;
Tarrant et al., 2012). This “piggy backing” of HCPs through a
puriﬁcation process on target recombinant protein products will be
product and bioprocess condition speciﬁc and, hence, the analysis
of HCP risk should include consideration and knowledge of the
following: (i) the target recombinant product itself; (ii) the HCPs
present in the culture harvest supernatant; (iii) the bioprocess and
downstream conditions to be utilized; and (iv) the risk of any given
HCP or HCP group (and knowledge of a critical threshold that
should not be exceeded for such HCPs/groups) remaining in the
ﬁnal formulated product. Although we focus the discussion here on
Chinese hamster ovary (CHO)-derived products and HCPs, such an
approach could be applied to the HCP proﬁle from any expression
system currently utilized (e.g., bacterial, fungi, insect cells, plant
cells). An overview of the route to the desired HCP proﬁle,
considering risk and different analytical technologies, is depicted in
Figure 1. How this links to risk analysis is described further below
and in Figure 2.
Figure 1. Overview of the HCP landscape in the context of biologics manufacture.
The left side of the figure shows a typical ELISA-based approach where a summed
value of the HCPs detected by the polyclonal antibody used is generated with a
probability of error (usually based on a Gaussian distribution as indicated). On the right
side, a mass spectrometry driven approach is depicted indicating the far larger
datasets of multiple species in a first mass spectra which themselves be further
fragmented to create spectra for identification. The differing challenges for these
differing approaches are highlighted.
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Analytical Technologies for HCP Analysis
Immunodetection-Based Methods
The most common method for the monitoring, detection, and
measurement of HCPs during bioprocessing manufacturing and in
ﬁnal biotherapeutic protein formulations destined for the clinic is
that of ELISAs (Shukla et al., 2008; Tscheliessnig et al., 2013; Wang
et al., 2009; Zhu-Shimoni et al., 2014). These high throughput, high
sensitivity, and highly selective assays have proved invaluable tools
for the industry to monitor HCP amounts in process development,
manufacturing and in ﬁnal product formulations, and are likely to
remain an important analytical tool in HCP analysis. Typically, an
ELISA is established using null host cell line isolates to immunize
animals and generate polyclonal antibodies (Tscheliessnig et al.,
2013; Zhu-Shimoni et al., 2014). The assumption in this approach is
that the null cell line HCP proﬁle will be similar to the recombinant
protein producing cell lines derived from the same host and as such
antibodies raised are likely to represent the HCP pool in the
recombinant cell line fermentation harvest material (Tscheliessnig
et al., 2013; Zhu-Shimoni et al., 2014). The fact that the majority of
HCPs in cell culture harvest material appear to be intracellular in
nature supports this assumption. The power of the use of ELISA for
the monitoring of HCPs during process development, validation,
and product testing, along with the potential limitations, has been
recently reviewed (Zhu-Shimoni et al., 2014) and others have
reported on efforts to increase the throughput of such immuno-
assay-based methods (Heo et al., 2014). Limitations of ELISA are
that in any anti-HCP antibody pool, there are not antibodies that
cover the entire spectrum of HCP species that may potentially be
present and that very weakly immunogenic, or non-immunogenic
species will not be detected. Further limitations of ELISA are
described by Zhu-Shimoni et al. (2014), who also highlight the need
for the use of orthogonal methods to ELISA for the measurement,
monitoring, and identiﬁcation of HCPs, particularly if one wishes to
undertake a risk-based assessment to identify critical HCPs. We also
note that there have been reports of a high prevalence of anti-CHO
HCP antibodies in human serum in which there has been no known
exposure to CHO-derived biotherapeutic proteins, questioning the
sensitivity or reliability of immunological-based systems for
detecting HCPs of high risk (Xue et al., 2010).
Any orthogonal techniques to measure and identify HCPs should
ideally be able to (i) detect protein concentrations across a wide
dynamic range, from very low concentrations of individual impurity
proteins to those of a much higher concentration, (ii) follow the
changing population and concentrations of HCPs throughout a
bioprocess, (iii) monitor/measure multiple protein analytes
simultaneously, and (iv) monitor/measure low concentration
HCPs when “swamped” by high concentration of the target
recombinant protein molecule. If a risk-based assessment of HCPs
is also to be undertaken then such methods should also be able to
identify those HCPs present at any stage of the bioprocess to allow
such an assessment to be undertaken. As ELISA is not able to
provide information on those HCPs present in any given sample, or
how the population of HCPs present changes throughout a process,
additional methods to complement ELISA clearly need to be
adopted if a more rigorous analysis of HCPs is to be undertaken or
required by the regulatory authorities.
A number of alternative or orthogonal analytical approaches are
currently used to complement ELISA measurement and monitoring
Figure 2. The risk assessment continuum is presented in the context of biopharmaceutical process development. In the risk assessment phase, risk is identified and assessed
using prior and existing knowledge to identify which parameters may impact the critical quality attributes (CQA). Then a risk mitigation or reduction action is taken. This could be
acceptance of the risk or process modification to ensure risk reduction. Then the risk assessment is repeated to determine if acceptable or not. As indicated, this is all mediated by
the organization’s analytical capability.
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of HCPs, although these are not universally applied to HCP analysis
during process development or validation (e.g., Capito et al., 2013;
Dickerson et al., 2011; Rey and Wendeler, 2012). The simplest are
probably the use of 1D- and 2D-polyacrylamide gel electrophoresis
(1D/2D-PAGE), together applied to investigate HCP dynamics
(Hogwood et al., 2013; Jin et al., 2010; Tait et al., 2012; Valente et al.,
2014). 2D-PAGE is widely used for the monitoring of HCPs during
process development, particularly the approach of 2D-DIGE,
whereby multiple samples can be compared on the same gel to
identify those HCPs that are present or increased/decreased
throughout a process (Grzeskowiak et al., 2009; Jin et al., 2010).
However, PAGE methods for the detection of speciﬁc proteins are
unable to detect low abundance HCPs and many HCPs can be
masked by the presence of the target recombinant protein or
product impurities. 2D-PAGE coupled with mass spectrometry
analysis of excised protein spots can be used to identify particular
spots on gels but again this relies upon detection of the spots of
interest and the sensitivity of the approach. The sensitivity of
different analytical techniques that might be applied to HCP
analyses is described by Tscheliessnig et al. (2013). Western blotting
of 1D and 2D gels can also be used to detect and determine those
HCPs present, but again as for ELISA, is limited by the pool of anti-
HCP antibodies used.
The Emergence and Rise of Mass Spectrometry-Based
Methods
A number of other recent orthogonal approaches to ELISA have also
been suggested and have recently been reviewed elsewhere
(Hogwood et al., 2014; Tscheliessnig et al., 2013). However, the
analytical technology that is emerging as the major orthogonal
technology to ELISA is mass spectrometry (Doneanu et al., 2012;
Joucla, 2013; Zhang et al., 2014b). Mass spectrometry requires a
highly skilled operator and access to expensive equipment; however,
the majority of analytical laboratories now contain high precision
mass spectrometry technology. The power of mass spectrometry is
the ability to monitor and identify multiple protein analytes in the
same sample rapidly and in a high throughput manner, although
obtaining absolutely quantitative data on such proteins using mass
spectrometry for multiple analytes remains a challenge. Never-
theless, mass spectrometry offers the opportunity to not only
monitor and measure the host cell protein and product impurity
proﬁle but the ability to identify what is, and is not, present in
any particular sample, including low abundance proteins. As such,
liquid chromatography coupled tandem mass spectrometry (LC-
MS/MS) has now been applied to the rapid monitoring of HCPs
(Doneanu et al., 2012). Technologies used in wider proteomic
studies, such as the labeling of peptides by methods such as iTRAQ,
can enhance the coverage of HCPs detected beyond that using a
standard 2D-PAGE approach (Tscheliessnig et al., 2012).
Recently, others have investigated using HCP enrichment
strategies combined with LC-MS/MS to improve the detection of
HCPs from antibodies generated from mammalian cell expression
systems (Thompson et al., 2014). Using such an approach, 19 HCPs
were detected in a therapeutic antibody preparation compared to a
single HCP identiﬁed without the enrichment strategy. This study
highlights the fact that with current ELISA and MS approaches
potentially important information about the HCP proﬁle and what
this contains is likely to be missed and cannot be included in any
risk-based assessment of the HCP proﬁle remaining in a
recombinant therapeutic protein preparation. Others have reported
the use of mass spectrometry as an orthogonal method to ELISA in
undertaking comparability studies of HCPs in drug substances
before and after process change (Reisinger et al., 2014). When
analyzing puriﬁed monoclonal antibody samples, Doneanu et al.
(2012) identiﬁed 33 HCPs by 2D liquid chromatography coupled to
mass spectrometry. Such HCPs in the puriﬁed therapeutic protein
could be considered critical HCPs, although this information alone
is not sufﬁcient to label these as such and further information (e.g.,
potential immunogenicity, enzymatic/protease activity) needs to be
considered to fully evaluate the risk of a given HCP being present.
The potential of mass spectrometry for monitoring HCPs during
process change has also been demonstrated by Zhang et al. (2014a)
who tracked individual HCPs from the cell culture harvest ﬂuid
through to a protein A elute pool and in a number of cases even
further downstream, identifying approximately 500 HCPs in the cell
culture ﬂuid and following these until no HCPs were identiﬁed in
the ﬁnal cation-exchange chromatography elute pools of the
puriﬁcation process. These authors estimate that the individual
HCP quantitation limit using the MS system they describe was
approximately 13 ppm. As such, the mass spectrometry conﬁg-
uration used here will still not provide full detection of all HCPs
present and the limit of detection is protein and/or peptide speciﬁc.
Connecting Improved Analytical Capability to Product and
Process Characterization
In identifying HCPs for the purpose of risk assessment, it is
important to consider the nature of the HCP itself. Although
immunogenicity is an obvious risk factor, intracellular and secreted
proteases may also be present that can result in the enzymatic
degradation of recombinant therapeutics (Dorai and Ganguly, 2014)
during fermentation or subsequently beyond if not completely
removed during downstream processing. In this case, it may be that
the HCP does present an immunogenic risk; however, it is also
possible that such proteases may themselves not be potentially
problematic, but the fact that the presence of these could result in
the generation of degraded product which could be inactive or in
the worst case scenario, harmful, that presents the risk. The ability
of new analytical technologies tomap andmonitor large numbers of
HCPs, therefore, offers the potential to completely re-think how we
use such information in monitoring, process development, and in
risk assessment. But how do we envisage such information be used
in the industrial sense to undertake risk assessment, inform process
development, and predict or reduce the potential risks to the
patient?
Process Considerations
The diversity of proteins contained within the HCP proﬁle manifests
different challenges for the process; many are enzymes and,
therefore, may catalyze degradation or other undesired alterations
to the product (e.g., reductases’ Kao et al., 2010; Trexler-Schmidt
et al., 2010). Equally, proteins may recognize and bind to certain
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epitopes on the product molecule (e.g., chaperone proteins) giving
rise to the possibility of HCPs that are associated with the product
molecule being carried through the process. This is a phenomena
now known to be the primary reason for HCPs making their way
through protein A afﬁnity chromatography (Nogal et al., 2012;
Tarrant et al., 2012).
Recognizing these process associated risks for HCPs is important
but the separation of perceived or theoretical risks for a given
product from those actual risks where resource should be devoted to
understand and mitigate such issues is central to effective process
development and subsequent monitoring and control. The critical
question, therefore, is how such understanding can be most rapidly
acquired for any given manufacturing process to provide safe and
efﬁcacious medicines.
As identiﬁed in the analytical section of this review, the
monitoring of host cell proteins remains a signiﬁcant challenge in
the production of biopharmaceuticals. In the absence of a single,
simple, ready to deploy assay for the monitoring of the complete
spectrum of these components, multiple methods are required.
Even so, there can remain unrecognized risks associated with these
components. Particular concern surrounds those components
which may be highly active in the body such as cytokines and highly
immunogenic species that present signiﬁcant risk to the patient
even at very low levels (Huang et al., 2009). Without high-end
analytical approaches for such HCP components, these speciﬁc
issues can be hard to identify and measure with sufﬁcient
sensitivity. It has been traditionally viewed that it is not cost
effective or robust to routinely use such techniques for process
development and monitoring activities; therefore, the strategy used
is to minimize these components to below accepted total HCP levels.
To select and prioritize assay deployment, it is critical to be aware
of where components are removed during the process sequence.
From a regulatory point of view, it is also an expectation that one
can describe the function of each operation in terms of impurity
removal. Table I provides a short summary of the issues associated
with host cell proteins during manufacture that have come to light
in recent years showing the complexity and challenges involved
around removing HCP components where we have created a
classiﬁcations structure.
Identification of Co-Eluting HCPs
This issue is deserving of speciﬁc attention as until recently, it was
poorly described in the literature. Publications by Shukla et al.
(2008) and Shukla and Hinkley (2008) led the way, showing the
importance of wash steps in disrupting HCP interactions in the
puriﬁcation of monoclonal antibodies via protein A afﬁnity
chromatography, while Pﬁzer highlighted a similar issue in an
E. coli/hydrophobic interaction chromatography step (Hunter et al.,
2009) and subsequently, the issue was followed up by several other
groups (Gagnon et al., 2014; Nogal et al., 2012; Tarrant et al., 2012).
Although the issue seems somewhat speciﬁc to the product and the
chromatographic resin backbone used, there are some generic
observations in the fact that there are clearly strong interactions
between certain host cell components and the product which
increase the likelihood of those impurities being co-puriﬁed. Levy
et al. (2014) have used antibody coated resins to study which HCP
components are most likely to behave in this manner; they observed
some degree of similarity between different antibody products and
the respective host cell proteins but also signiﬁcant differences.
Gagnon et al. (2014) sought to identify the causative agents,
identifying chromatin as a strong binder of protein A chromatog-
raphy resins and giving rise to difﬁculties controlling the
performance of this step. Such insights are directly applicable to
process development and risk management.
Regulatory Guidance and Risk Evaluation
The International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human Use
(ICH) guidance Q9 Quality Risk Management outlines the key
principles in understanding and managing the risk associated with
the manufacture and supply of pharmaceutical products. This
guidance outlines the key principles of risk assessment (identi-
ﬁcation, probability, and severity) coupled to risk management
(reduction and mitigation). In terms of host cell proteins (HCPs), it
is an extremely complex proposition to adequately deﬁne and
control the risk factors when considering the implications of HCPs
and the potential for impact on product critical quality attributes
(CQAs) as well as product quality attributes (PQAs). Both are
deﬁned in ICH guidance Q8 (R2). CQAs are “physical, chemical,
biological, or microbiological properties or characteristics that
should be within an appropriate limit range or distribution to
ensure desired product quality.” PQAs are described as “molecular
or product qualities that deﬁne the quality of the product.” This
basically is a methodology for evaluating the product and process-
derived components that are present in the material administered to
the patient. The determination of the risk/beneﬁt proﬁle of a
product is vital—does the beneﬁt to the patient outweigh the risks?
The difﬁculty is of course understanding the risk and managing the
uncertainties, and the knowledge gaps. Risk is deﬁned on the basis
of occurrence or harm and severity of that harm (ICH Q9). In the
Table I. Selected recent publications in characterization and understanding of process-related impurities.
Subject matter Publications Author’s affiliation
Identification of
critical HCPs
Levy et al. (2013), Aboulaich et al. (2014), Eon-Duval et al. (2012), Wang et al. (2009),
Valente et al. (2013), Beatson et al. (2011), Bomans et al. (2013)
Genentech, MedImmune, Uni. Delaware, Merck
Serono, Pfizer, Kings, Roche, Merck (US)
HCP Process
interactions
Shukla et al. (2008), Hunter et al. (2009), Aboulaich et al. (2014), Hogwood et al. (2013),
Nogal et al. (2012), Tait et al. (2012), Tarrant et al. (2012), Trexler-Schmidt et al. (2010),
Joucla et al. (2013), Levy et al. (2014), Gagnon et al. (2014)
Bristol-Myers Squibb, Pfizer, MedImmune, UCL,




Kao et al. (2010), Dorai et al. (2011), Sandberg et al. (2006), Trexler-Schmidt et al. (2010),
Gao et al. (2011), Robert et al. (2009)
Genentech, Centocor, Biogen Idec, Biovitrum, Merck
Serono
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case of pharmaceutical product development, a PQA must be
assumed to be critical until sufﬁcient data are generated. Managing
the uncertainty is a challenging task but vital in managing the risk
of adverse events to patients. The assumption of criticality, and by
deﬁnition a need for control is a philosophy that prioritizes patient
safety, is deﬁned as a “precautionary principle” (Martuzzi and
Tickner, 2014). This principal when applied to therapeutic products
is captured in the statement “rather than presume that speciﬁc
substances are safe until proven dangerous, the precautionary
principle establishes a presumption in favor of protecting the
patient health in the face of uncertainty” (Rosenberg et al., 2012). In
order to manage and mitigate the risk factors, understanding the
critical elements is a key ﬁrst step. The principle mechanism of
concern for HCPs is twofold; ﬁrstly, potential immunogenicity, and
secondly, the concern that HCPs could act as agents of modiﬁcation
of the desired product.
Given that HCP is a PQA and a CQA until proven safe the ﬁrst
logical step in the risk assessment process is the establishment of an
appropriate limit, range, or distribution to ensure consistent
delivery of a product delivering desired product quality. In terms of
HCPs, the assumed straight-forward approach is tomeasure directly
the HCP level by a proven method and set appropriate limits. The
question is which one method achieves this for HCPs, given the
potential for heterogeneity of the HCP population and the
possibility of product/HCP binding. The next step in risk
assessment is development of knowledge to allow for science-
driven assessment and to minimize potential uncertainties. The
potential complexity of the HCP population is a signiﬁcant factor.
For example, it is estimated that the Chinese hamster genome
contains 24,044 genes of interest in relation to HCP expression
(Lewis et al., 2013) and E. coli has approximately 4,300 genes
(Blattner et al., 1997). Just at a genomic level, the complexity is
already potentially overwhelming. It is not feasible or possible to
consider each gene expression product in isolation. This is then
further complicated at the proteome level when the expressed
proteins are exposed to additional modiﬁcation. It has been
reported that one protein was found to have more than 20 different
modiﬁed forms (Godovac-Zimmermann and Brown, 2001).
Examples of the types of modiﬁcations that can generate HCPs
with different biochemical properties, and thus, further complicate
the HCP evaluation process, include glycosylation, phosphorylation,
acetylation, sumoylation, and truncations. This is most likely an
underestimation; a well characterized monoclonal antibody
theoretically has the potential for (9,600)2 post-translational
modiﬁcations (Kozlowski and Swann, 2006). So, what chance is
there of the identiﬁcation of 24,044 (9,600)2 potential variants?
How are the critical HCPs selected and evaluated, and most
importantly, controlled?
Establishing HCP Impurity Specifications
The “traditional” practice is to set a target of 100 ng/mg therapeutic
protein as an acceptable limit for residual HCP. A key question,
therefore, is what forms/species of HCPs comprise this 100 ng/mg.
The characterization of all residual HCPs typically is a difﬁcult and
complex analytical challenge as previously highlighted. It is unlikely
that one method will be sufﬁcient; this is especially true in the
process characterization phase of the product development life
cycle. Consequently, the most signiﬁcant deliverable is knowledge,
of both product and process. In terms of HCPs, this would equate to
characterization of the types and masses of individual HCPs to the
extent where potential interactions with product or patients could
be assessed. It is not just a case of making a measurement of generic
mass of non-product-derived proteins and, hence, then by
deﬁnition other or “HCP” proteins present in the process samples.
Rather, an understanding of the dynamics of the HCP protein
population through the process ﬂow from cell substrate propagation
through to ﬁnal drug product is required. This, in itself, is then part
of the narrative as the key element is determination of risk to
product attributes due to the presence of the HCPs. So, are the HCPs
in themselves potentially immunogenic and, hence, impacting on
product safety? Do any of the individual proteins forming the
general mass labeled HCP have the potential to modify the
therapeutic product by enzymatic activity or forming an association
with the product, such as hitchhiker antigens? (Hunter et al., 2009;
Luhrs et al., 2009). The fundamental question is how reasonable
assessments as to the potential risk can be made when considering
the complexity and the potential for multiple interactions between
product/process and residual HCPs. Yet, other considerations in
relation to HCPs include the potential adjuvant characteristics. Such
properties could result in generation of anti-HCP antibodies or even
result in anti-product antibody formation resulting in loss of
product efﬁcacy. Both outcomes could lead to an increase in the risk
of adverse events.
The above leads us to question whether a 100 ng/mg target is
really acceptable? Should the deﬁnition be more speciﬁc and based
upon amore detailed understanding of the HCP population present?
The truth is that the actual impact of residual HCPs cannot currently
be fully understood. However, the best practice is to assume a worst
case scenario and act accordingly. This dictates that the lowest
reasonable level of residual HCP as assessed by several methods
must be the goal. It is poor science just to assume low risk because a
level of 100 ng/mg has for related products been determined as safe.
A further level of characterization should be attempted to develop
sufﬁcient knowledge to allow for science-based risk assessment. It
is, therefore, logical to develop the capability to characterize and
quantify HCPs early in the product life cycle. These tools are needed
to facilitate process development with a focus on HCP reduction and
control. To properly assess the risk factors, it is important to
understand the mechanisms for generation and selection of
identiﬁed HCPs during the upstream and downstream processes. It
is essential to understand as far as is reasonably possible the nature
of the HCP population during the product development
progression. For example, it is typical that the product used for
pre-clinical studies is less pure than that used for phase III and
beyond (when the manufacturing process has been further
developed), and is likely to have higher HCP levels and more
species of HCP. At early stages, some companies may believe it is
sufﬁcient to use commercial ELISA kits and set speciﬁcations at
100 ng/mg. This approach does give a measure of a level of HCP but
in reality, each process and product would beneﬁt from its own
speciﬁc HCP assay method using null cell lines (not producing
product) to develop immunogen. Any anti-HCP antibodies must be
characterized to demonstrate speciﬁcity in terms of what
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proportion of the total HCP population is covered. A 2D gel followed
by Western blotting with the anti-HCP antibody, though highly
variable and not very quantitative, is a fairly common means of
demonstrating the degree of coverage. The higher the proportion of
the HCP population bound by the antibodies the greater the
conﬁdence and utility in the method for speciﬁcation setting and
demonstration of process control. If the investment in development
of such robust methodologies for HCP detection and character-
ization is delayed until pre-phase III clinical trials the opportunity of
knowledge generation is lost. This represents a potentially serious
omission considering a primary aim in product development is the
generation of sufﬁcient knowledge to demonstrate control. In the
case of HCPs, if the control is well demonstrated then routine testing
may not be required on a regular basis and so consequently there is
a return on early investment in HCP analytic capability for both
qualitative and quantitative assessments.
The Basis for a Risk-Based Approach
The goal of risk evaluation is to provide a reasonable scientiﬁc basis
for establishing the levels of a product attribute that would be
expected, with a high degree of conﬁdence, to have no adverse
impact on product quality and, hence, performance. It is also
essential that the assessment of quality characteristics should be
performed throughout the product lifecycle, even if a favorable
safety/efﬁcacy proﬁle has been established. Continuous improve-
ment to PQAs is encouraged so as to produce the best possible
product. The difﬁculty in particular with HCPs is the complexity
and the related uncertainty factors. It is not possible to fully predict
potential immunogenicity given the range of different patient
factors, so, severity will always remain high. The lack of deﬁnition of
speciﬁc risk does not allow for a “wait and see” approach. A
proposed risk management process is summarized in Figure 2.
The ICH guidance Q6B (1999) Speciﬁcations state that test
procedures and acceptance criteria for biotechnological/biological
products, guides the setting of acceptance criteria and speciﬁcations
in which HCPs as process (cell substrate derived) impurities are
considered. This gives a very high level limit test driven approach,
although in the case of HCPs, this needs further levels of
consideration, principally due to the rapid developments in protein
analytical characterizationmethods. It is far easier today tomap out
the complete proteome environment than it was in 1999 when the
guidelines were issued. There now exists the capabilities to resolve
to very low levels with new methods in development. The hope is
that this will yield a better understanding and enhance the ability of
predicting the immunogenicity or product modiﬁcation capabilities
of individual HCPs (Xing et al., 2009).
However, this still leaves the question as to how to assess the risk
of the presence of very low levels of HCP impurities. A key approach
is to design quality into the process rather than just performing
analysis on process derived samples. This Quality by Design (QbD)
approach is in alignment with the ICH guidelines 8(R2), 10, and 11
and is in essence a systematic approach to generate process and
product knowledge to deﬁne an acceptable process operational or
design space. It is important that the data leading to the assignment
of criticality for a PQA is derived from multiple sources; these
include the direct testing and characterization data sets and also
literature reviews, published scientiﬁc knowledge and any available
animal/human pre-clinical and clinical studies. However, given the
potential complexity coupled to the degree of uncertainty, it is
generally rational to consider HCPs as a CQA. Given this deﬁnition
any process parameter relating to HCP formation and removal
should then automatically be designated as a critical process
parameter (CPP) and controlled appropriately.
In terms of the HCP analytical tool kit and risk assessment,
the key ﬁrst step is to develop a holistic view of the overall cell
substrate derived HCP population. In particular, development of the
understanding of how changes in the expressed HCP population
relate to the producer cell line is a critical element in the risk
management process. The risk analysis process would then be
driven ﬁrstly by the ability to detect and identify the total HCP
population. This would then facilitate a process design to maximize
the efﬁcient removal of HCP species and develop a robust process
capability. From this, speciﬁc HCPs of interest (those found to be
associated with elevated risk) might be selected for further
consideration. Utilization of polyclonal antibody-based ELISA and
Western blot methodologies are invaluable in terms of mapping the
potential diversity of HCP populations from initial cell substrate
through to puriﬁed Drug Substance (Krawitz et al., 2005).
A Structured Approach to Establishing HCP-Associated
Risk
The knowledge acquired from the deployed analytical methods can
be used to rank HCPs based upon the following:
(1) Severity—including immunogenicity (microbial far greater
than mammalian, within which rodent far greater than human
or primate), biological activity (e.g., hormones), and product
interactions (e.g., proteases).
(2) Detection—how easily is the class of HCP or speciﬁc HCP
detected and quantiﬁed?
(3) Abundance—what is the amount of an HCP or HCP class?
HCP Severity
In such a ranking, the expression system is likely to inﬂuence the
determination of HCP risk. Consequently, for E. coli HCP, the
likelihood of an immunological reaction is higher because of the
higher probability of a “foreign” epitope being recognized by a T
cell. The result of a ﬁrst exposure to an antigen is the generation of
antibodies and induction of memory cells, and this priming leads
to an immune response on re-exposure. Other immunological
reactions may manifest as an acute hypersensitivity reaction
leading to anaphylaxis, cytokine release syndrome, and other
challenging immune responses (Huang et al., 2009; Singh, 2009). It
is also important to consider that potential adjuvant activity can
arise through multiple mechanisms, including the presence of
microbial impurities in therapeutic protein products. Although the
likelihood of this is very low, this mechanism could in fact enhance
anti-product antibodies increasing the risk of clinical complications
and also reducing the product efﬁcacy (Lundstr€om et al., 2014). The
difﬁculty in assessing the risk factors relating to HCPs and potential
immunogenicity derived directly from the presence of HCPs
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themselves, and also product-derived species arising from HCP-
mediated modiﬁcations, is the knowledge gap. How can the
potential for immunogenicity be assessed? The US Food and
Drug Administration Guidance for Industry Immunogenicity
Assessment for Therapeutic Protein Products details a risk-based
approach to provide investigators with the tools to develop novel
protein therapeutics and evaluate the potential need for tolerance-
inducing protocols when severe consequences result from
immunogenicity. The key to the approach is combining analytical
methods not only for direct HCP detection and quantiﬁcation,
but also highlights the need for methods capable of assessing
antibody formation or allergic reactions to HCPs administered with
the product. The analytical methods are required at the earliest
stages of the product lifecycle (pre-clinical) to allow for the
monitoring of potential impact of HCPs in animal and early clinical
studies.
In terms of deﬁning risk, the initial assumptions would be that
severity of the presence of HCP is set to the highest level. This
uncertainty creates elevated risk driving the need for accurate
measurement of HCPs; this need can only be lessened on the basis
of actual knowledge (Rosenberg, 2012).
Detection and Abundance—Generation of the HCP
Polyclonal Serum
In terms of HCP, estimation of abundance is a critical knowledge
deﬁning activity which as stated is performed by ELISA; hence,
generation of the polyclonal used is the singularly most important
factor in the analytical method. The type of (null cell-derived)
immunogen used is critical, for example, the point in the mock
process stream at which it is derived—from an early stage of the
DSP, the middle or at an end stage, or a mixture/blend from
multiple parts of the process? Factors such as these must be
considered when developing an antibody-based method of HCP
quantiﬁcation. In certain cases, the adjuvant used to immunize the
donor animal has also been demonstrated to inﬂuence the afﬁnity of
the antibodies or produce a higher population of antibodies for the
speciﬁc HCP (Lundstr€om et al., 2014). From a risk assessment
perspective, the criticality of the HCP analytical methods dictate
that the best practices are used.
The Impact of a Risk-Based Approach to HCP Analysis
The combination of these factors allows for a risk assessment value
to be determined. At the start of a product lifecycle, this will be
anticipated to be at its highest, with the most signiﬁcant knowledge
gap. As methods are reﬁned or new methods coupled to experience
gained from process and product usage, the knowledge generation
should close identiﬁed gaps. The ability to better access the
potential for product/process/HCP interactions will be realized
which is a key foundation for scientiﬁc risk-based assessments. It is
important to focus on the product being deﬁned in the ICHQ6 sense
containing both product-derived and process-derived impurities to
enable a level of risk acceptance to be tolerated as knowledge
increases. The key part of the risk management approach as
delineated in ICH Q9 is the utilization of the increased knowledge/
analytical methodology to seek ways of reducing the risk and
developing a mitigation strategy. For HCP, a potential risk
mitigation strategy could include the following:
(1) Engineering of the cell substrate, purposely deleting speciﬁc
genes that are not required for cell function in terms of
producing the deﬁned product, or speciﬁc deletion of genes for
problematic HCPs (Humphreys et al., 2004) such as proteases
that are proven to cause unwanted product modiﬁcations.
(2) Improving process performance to eliminate and remove HCP
impurities. This may result in lower product yields, but in
terms of process priorities safety is the prime driver in process
development.
(3) Continuously evaluating and developing analytical methods for
assessment of process performance and the impact of product
purity during clinical performance, and ensuring that these
data are used to reﬁne process performance. Examples could
include speciﬁcally targeting a speciﬁed HCP in order to
eliminate or control to a tighter tolerance.
The emphasis is that the risk reduction strategy supports and
facilitates the adequate control of the risk identiﬁed due to the
HCPs. The information gathered is then incorporated into the
process control strategy as this is developed in conjunction with
the product manufacturing process and deﬁnition of the process
design space.
However, risk can never be eliminated and instead it must
be minimised by deﬁning what is acceptable using a scientiﬁc
rationale to justify the identiﬁed risk. The essential mitigation will
be demonstration of control typically by speciﬁcations which deﬁne
safe levels of critical HCPs (typically based upon knowledge of what
has been present in clinical batches). This should be linked to
process performance and ensuring the process operates within the
same operation space (or a more stringent version with tighter
ranges) used for the manufacturer of the clinical batches.
The Demands of HCP Analysis for Standards and
Biosimilars
The HCP population and its potential to inﬂuence product attributes
is a signiﬁcant consideration in terms of development of biosimilar
products. Proving “similarity” is an onerous analytical challenge
with such a high degree of complexity arising in product-related
impurities and HCPs. It requires the deﬁnition of the originator
product alongside a proposed biosimilar to make this case.
Analogous considerations must be made for the originator product
where a process improvement is proposed. The creation of a
reduced impurity proﬁle product might be an option in both
scenarios but will have consequences in terms of the regulators
perception of such products and the amount of clinical data
expected to support approval.
These are difﬁcult propositions to answer in a generic manner
and will require a case by case consideration. However, it seems a
logical consideration that the fewer impurities such as HCPs the
greater the positive impact of product attributes such as safety and
reduction in potential immunogenicity and in these situations
standards in terms of materials and analytical methods could be of
great assistance. This must be balanced against the fact not all HCPs
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are equal in the risk they present, as we have identiﬁed. This is
consistent with the intentions outlined in the ICH guidance Q5E
which states “Improvement of product quality is always desirable
and encouraged.”
A Proposed Route Forward
Combining risk indices associated with the host cell proteome
suggested in Figure 3 to include immunogenicity, biological activity,
and a measure of the interaction with the product during
manufacture and storage, while a huge task due to the number of
protein species, is computationally possible assuming themethods to
calculate these indices can be determined and agreed upon. As the
utility of proteomic databases grow alongside existing genomic
information and algorithms to predict immunogenicity (Bailey-
Kellogg et al., 2014) andprotein interactions (Wass et al., 2010) itmay
not be that distant an aspiration to standardise some of the matrices
indicated in Figure 3 and use the input from mass spectrometry to
provide quantitative indices of risk that a particular HCP proﬁle
might pose. It would be critical that such indices could be agreed
upon to avoid their proliferation which would rapidly mean such an
approach be rendered meaningless. This might follow an ICH model
to create agreed approaches/indices, although this would require a
custodian of this informationwhichwouldmost likely need to involve
national standards laboratories. It would enable generic databases to
be generated (e.g., relating to the CHO proteome) to quantify a
summed HCP risk value based on mass spectrometry data from a
user, hence, making it possible for information which might be
regarded as commercially sensitive to remain conﬁdential.
Conclusion
Without knowledge and supportive data, the HCP population has to
be assumed to be a critical product attribute in the assessment of
risk. The only means of changing the uncertainty rating in terms of
effects on product safety is a risk reduction strategy based on
utilizing the best possible analytical methods as soon as is feasible
in the product lifecycle development. Given the assumed success of
a product then the data generated in terms of HCP type, distribution
and relative abundance will prove invaluable later when assessing
risk of process changes/improvements, comparability studies, and
many other situations that will occur during a product lifecycle.
Additionally, such analytical tools for HCP characterization and
quantiﬁcation are invaluable in terms of creating a deﬁned design or
control space for process operation to ensure the best possible
product generation at all phases.
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